Cystitis Cystica Glandularis: Evaluation and Management
Cystitis cystica glandularis should be diagnosed via cystoscopy with biopsy, managed initially with transurethral resection (TURBT), and followed by consideration of COX-2 inhibitor therapy (celecoxib) to prevent recurrence, with close surveillance cystoscopy every 3-6 months given the uncertain malignant potential.
Diagnostic Approach
When to Suspect the Diagnosis
Look for patients presenting with:
- Persistent lower urinary tract symptoms (frequency, urgency, dysuria) despite negative urine cultures 1
- Hematuria (microscopic or gross)
- Voiding difficulty or obstructive symptoms 2, 3
- Bladder mass on imaging
- Recurrent "cystitis" unresponsive to antibiotics
Essential Diagnostic Workup
Cystoscopy is mandatory for definitive diagnosis 1. The condition appears as:
- Multiple edematous masses, often on the trigone and bladder neck 4
- Cystic and nodular lesions involving bladder urothelium 5
- Can mimic low-grade urothelial carcinoma 6
Critical pitfall: Do not rely on urine cytology alone—it has poor sensitivity and may be equivocal in up to 21% of cases 7. Cystoscopy with biopsy is the only reliable diagnostic method.
Imaging considerations:
- Ultrasound or CT urography to assess for hydronephrosis if obstructive symptoms present 2, 5
- Upper tract imaging if bilateral ureteral orifices are involved 4
Management Algorithm
Initial Treatment: Transurethral Resection
Complete TURBT is the first-line treatment 4, 6, 8. This serves both diagnostic and therapeutic purposes:
- Obtain tissue for histopathologic confirmation
- Differentiate from urothelial carcinoma (particularly intestinal-type cystitis glandularis)
- Reduce tumor burden
Novel Adjunctive Therapy: COX-2 Inhibitors
Consider oral celecoxib (COX-2 inhibitor) as adjunctive therapy, particularly for:
- Extensive disease involving multiple bladder regions 4
- Recurrent disease after initial resection 8
- Preoperative tumor reduction to facilitate complete resection 4
The evidence supporting this approach is emerging but promising:
- One case demonstrated marked tumor volume reduction after 6 weeks of preoperative celecoxib, with resolution of voiding difficulty and pain 4
- Immunohistochemistry shows COX-2 expression in cystitis glandularis epithelium, suggesting a pathophysiological role 8
- Combination of celecoxib with TURBT achieved remission in documented cases 8
Dosing consideration: While specific dosing isn't detailed in the evidence, standard COX-2 inhibitor dosing for inflammatory conditions would apply (typically celecoxib 200 mg daily or twice daily).
Management of Recurrent Disease
Cystitis glandularis has a notable recurrence rate. For early recurrence (within 3-4 months):
Option 1: Repeat TURBT with intravesical gemcitabine 6
- This approach borrows from bladder cancer management protocols
- Limited evidence but has been used successfully in case reports
Option 2: Repeat TURBT with COX-2 inhibitor therapy 8
- May be preferred given the specific pathophysiology
Option 3: For pediatric cases or severe inflammation, consider adding oral corticosteroids 2
Severe/Refractory Cases
For florid disease causing:
- Bilateral ureteral obstruction: Urgent decompression with percutaneous nephrostomies 5
- Irreversible renal injury: May require renal transplantation 5
- Persistent obstruction despite medical/endoscopic therapy: Partial cystectomy or cystectomy may be necessary 8
Surveillance Protocol
Close surveillance is mandatory given:
- Uncertain malignant potential (possible progression to adenocarcinoma has been documented) 2
- High recurrence rates 6
Recommended surveillance schedule:
- Cystoscopy at 3 months after initial treatment 6
- If clear, repeat at 4-6 months 6
- Continue surveillance cystoscopy every 3-6 months for at least the first 1-2 years
- Consider annual surveillance thereafter if disease-free
Monitor for:
- Recurrent cystic/glandular lesions
- Development of high-grade features
- Obstructive symptoms requiring intervention
Key Clinical Pearls
Do not mistake for simple cystitis: Negative urine cultures with persistent symptoms should prompt cystoscopy 1
Rule out malignancy: Cystitis glandularis can mimic urothelial carcinoma—histopathologic confirmation is essential 6
Assess for obstruction early: Check post-void residual and upper tract imaging if voiding symptoms present 2, 5, 3
COX-2 inhibitors represent a paradigm shift: This is the first medical therapy showing promise for this traditionally surgical condition 4, 8
Avoid unnecessary cystectomy: With COX-2 inhibitors and close surveillance, bladder-sparing approaches are increasingly feasible 8